Ipamorelin: The Selective Growth-Hormone Secretagogue

The short version

Ipamorelin is a synthetic five-amino-acid peptide that activates the ghrelin receptor (GHS-R1a) on the pituitary gland, triggering a short pulse of growth hormone (GH) release. It was first characterized in 1998 as the first GH-selective secretagogue — meaning it releases GH without meaningfully raising cortisol or prolactin, unlike earlier compounds in its class. It has never been approved as a drug for any use; its only published Phase 2 human trial, testing it after bowel surgery, missed its primary efficacy endpoint. It is sold today strictly as a research chemical, for laboratory use, with no pharmaceutical quality assurance behind the material.

This page summarizes what has actually been studied — mostly in rats, swine, and a small number of human volunteers — and states plainly where the evidence stops. It does not recommend a dose for any person, and none of its content is medical guidance.

What it is

Ipamorelin's full sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2 — a pentapeptide built by removing the central Ala-Trp dipeptide from an earlier compound, GHRP-1, and substituting alpha-aminoisobutyric acid (Aib) at position one along with D-configured amino acids at two other positions. Those substitutions make the peptide resistant to the enzymes that would otherwise break it down quickly, extending its usable half-life to roughly two hours ^[4].

It is a selective agonist at the growth hormone secretagogue receptor (GHS-R1a) — the same receptor activated by the natural hunger hormone ghrelin. Its founding 1998 characterization tested it in primary rat pituitary cells, anaesthetized rats, and conscious swine, and found it released GH about as potently as an older compound, GHRP-6, without the accompanying rise in ACTH or cortisol seen with that older peptide, even at doses more than 200 times its GH-triggering dose ^[6]. That selectivity is ipamorelin's defining pharmacological feature and the reason it is studied and marketed separately from earlier, less selective GH secretagogues.

How it works

When ipamorelin binds GHS-R1a on pituitary somatotroph cells, it triggers a single, time-limited pulse of growth hormone release rather than a sustained elevation — human pharmacokinetic modeling found the GH response peaks about 40 minutes after dosing and resolves within a few hours ^[4]. Because this mechanism is distinct from, and complementary to, the separate GHRH receptor pathway, ipamorelin is frequently studied and used alongside GHRH-analog peptides such as CJC-1295, on the theory that stimulating both pathways produces a larger combined GH pulse than either alone.

The same GHS-R1a receptor is also expressed outside the pituitary — in the gut, in pancreatic islet cells, and in hypothalamic appetite circuits — which is why ipamorelin's effects are not limited to growth hormone. A rat study found dose-dependent increases in longitudinal bone growth rate across three dose levels, without any detectable change in circulating IGF-1 or bone-turnover markers, suggesting at least part of its skeletal effect operates locally or through the GH pulse itself rather than through a sustained systemic IGF-1 rise ^[5]. A more recent 2026 narrative review found that ipamorelin combined with the GHRH analog CJC-1295 improved muscle-contraction strength in a mouse model of glucocorticoid-induced muscle loss, though the review was explicit that this evidence is limited to animal studies and that safety and dosing data in humans remain unknown ^[7].

What the research shows

Most recent in-vivo finding (2024). In a ferret model of chemotherapy-induced weight loss and nausea, intraperitoneal ipamorelin reduced cisplatin-induced body-weight loss by roughly 24% during the delayed phase of the model, but produced no anti-emetic effect on either the acute or delayed phase — in contrast to a related compound, anamorelin, which reduced acute-phase nausea through a separate central mechanism in the same study. This is the most recently published in-vivo ipamorelin study ^[1].

Human efficacy trial (2014). The only published Phase 2 randomized controlled trial of ipamorelin enrolled 114 adults recovering from bowel resection surgery, dosing 0.03 mg/kg intravenously twice daily for up to seven days. It missed its primary endpoint: median time to the first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo, a difference that did not reach statistical significance. Adverse events were reported in 87.5% of the ipamorelin group versus 94.8% of the placebo group — no ipamorelin-specific safety signal emerged in this short perioperative window, but efficacy for this indication was not demonstrated ^[3].

Human pharmacokinetics (1999). In eight healthy male volunteers per dose level, five short intravenous infusions ranging from roughly 4 to 140 nmol/kg produced dose-proportional kinetics: a terminal half-life of about two hours, and a single discrete GH pulse peaking around 40 minutes after dosing. This remains one of only a handful of published human ipamorelin datasets ^[4].

Bone growth in rats (1999). Fifteen days of subcutaneous dosing at three dose levels dose-dependently increased longitudinal bone growth rate in adult female rats — from 42 micrometers/day at baseline to as much as 52 micrometers/day at the highest dose — without any measured change in total IGF-1, IGF-binding proteins, or bone-turnover markers ^[5].

Founding characterization (1998). The original pharmacology paper established ipamorelin as the first highly GH-selective secretagogue: potent GH release in rat pituitary cells, anaesthetized rats, and conscious swine, with no significant rise in ACTH or cortisol even at doses more than 200-fold above its GH-triggering dose ^[6].

Class-level cardiovascular safety signal (2015). A related but distinct GHS-R1a agonist — not ipamorelin itself — produced dose-dependent myocardial degeneration and necrosis in rats after 28 days of chronic dosing, detectable by histopathology and electron microscopy and accompanied by an elevated cardiac injury biomarker at the highest doses. This is the clearest chronic-dosing cardiovascular safety data available anywhere in ipamorelin's receptor class, and it is why this desk treats long-term systemic GHS-R1a agonism as a scrutiny-worthy question rather than a settled one ^[2].

Combination-protocol animal data (2026). A narrative review from an orthopaedic and sports-medicine perspective found that ipamorelin combined with the GHRH analog CJC-1295 improved maximal muscle tetanic tension in a mouse model of glucocorticoid-induced muscle loss — but the review's own conclusion was that evidence remains limited to animal studies and that meaningful safety and dosing research in humans is still required before any clinical recommendation can be made ^[7].

Reported effects, cautions & safety

Community reports about ipamorelin — usually describing it in combination with CJC-1295 — are extensive online, even though controlled human data are sparse. These are anecdotal, not clinical evidence, and none of them specify a verified dose, source, or protocol.

Reported benefits (anecdotal, not clinical evidence): The most consistently described effect is deeper, more restorative sleep, with reports of faster sleep onset and feeling noticeably more rested — often within the first one to two weeks of a pre-bed protocol. Vivid dreaming is also commonly described in the early weeks, generally settling as sleep patterns stabilize. Some reports describe faster physical recovery between training sessions and reduced post-training soreness, and a smaller group describe a gradual shift toward a leaner body composition over several months — though this is confounded by concurrent diet and training in every such report.

Reported adverse effects (anecdotal, not clinical evidence): A warm flush across the face, neck, or upper chest shortly after injection is widely described, along with occasional tingling or numbness in the hands and feet, mild water retention, increased hunger in the hours after dosing (consistent with ipamorelin's ghrelin-receptor mechanism), transient dizziness or fatigue, and localized injection-site irritation. Some long-term community reports describe a diminishing subjective effect after three to four months of continuous use, which is part of the reasoning behind on/off cycling protocols discussed in research communities.

Cited cautions from the clinical and preclinical literature:

• Active or recent malignancy. Growth hormone stimulates hepatic IGF-1 production, a well-characterized mitogen; ipamorelin's founding characterization documents potent, repeatable GH release ^[6], and its GH-axis engagement is also demonstrated in bone-growth work ^[5]. No ipamorelin-specific tumor-promotion study exists in any species — this is a mechanistic, class-level caution, not an observed event.
• Diabetes or impaired glucose tolerance. Growth hormone is a counter-regulatory hormone that can reduce insulin sensitivity at sustained levels ^[6]. Ipamorelin also engages tissue outside the pituitary, which introduces a second metabolic pathway whose net glycemic effect in a person with pre-existing glucose dysregulation has not been evaluated in any published human study.
• Cardiovascular disease or significant edema. A structurally related GHS-R1a agonist produced dose-dependent myocardial injury in a 28-day rat study ^[2] — a class-level signal, not an ipamorelin-specific one, but there is no long-duration cardiovascular safety study of ipamorelin itself in any species.
• Appetite dysregulation or obesity-related conditions. Ipamorelin shares its receptor with the body's primary hunger hormone ^[6], and community reports of increased appetite after dosing are consistent with that mechanism.
• Unknown long-term human safety and unverified material purity. The entire controlled human ipamorelin dataset is a single short perioperative trial ^[3] and a single acute pharmacokinetic study ^[4] — no Phase 3 trial has ever been conducted. Research-grade ipamorelin from unregulated suppliers carries no pharmaceutical quality assurance for purity, identity, or sterility.
• A relative safety note. Unlike earlier growth-hormone-releasing peptides, ipamorelin's founding characterization found no meaningful rise in cortisol or prolactin even at very high doses ^[6] — a genuine pharmacological advantage over less selective compounds in its class, though not evidence of an absence of all off-target effects.

Where it fits in Research Peptide Fundamentals

Ipamorelin is the lead compound on this desk because it is the one most often handled, reconstituted, and self-administered by injection in ongoing research-community use — which makes the reconstitution-and-handling frame directly relevant to it. Its lyophilized powder form, the absence of any pharmaceutical quality assurance in its supply chain, and the near-total absence of long-term human safety data together mean that how a given vial was reconstituted, stored, and handled may matter as much to a research outcome as the peptide's underlying pharmacology. MOTS-c sits at a very different evidence stage — its human data are observational rather than interventional — while retatrutide shows what a peptide looks like once it enters formal, pharmacy-controlled clinical development. See the comparison page for the full picture.